Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Small Cell Lung Carcinoma 3Recurrence 2Ovarian Neoplasms 2Solid Tumors 1Sarcoma 1Lymphoma, Non-Hodgkin 1Carcinoma, Hepatocellular 1

Interventions

Paclitaxel 177Carboplatin 177Bevacizumab 72Topotecan 55liposomal doxorubicin 54Gemcitabine 53Cisplatin 46Docetaxel 39Cyclophosphamide 37olaparib 32Filgrastim 31pembrolizumab 29Doxorubicin 26niraparib 24Taxes 23Drug Therapy 23Peripheral Blood Stem Cell Transplantation 20Etoposide 17veliparib 15Nivolumab 14sargramostim 13Surveys and Questionnaires 13Immunoglobulin G 13Disulfides 13pazopanib 12Ifosfamide 12Albumin-Bound Paclitaxel 12durvalumab 11atezolizumab 11Trabectedin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Ovarian Neoplasms × chiauranib × Clear all
NCT03901118 2021-03-19

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

Chipscreen Biosciences, Ltd.

Phase 2 Completed
47 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT03166891 2020-01-18

Phase Ib Study of Chiauranib in Patients With Ovarian Cancer

Chipscreen Biosciences, Ltd.

Phase 1/2 Completed
25 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡